Healthcare provider profile · identity verified

Thomas T. Pham, MD

Internal Medicine · HARBOR CITY, CA · NPI 1598813404

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	803	336
Amlodipine Besylate	Amlodipine Besylate	468	186
Lisinopril	Lisinopril	272	112
Losartan Potassium	Losartan Potassium	253	105
Rosuvastatin Calcium	Rosuvastatin Calcium	238	96
Levothyroxine Sodium	Levothyroxine Sodium	184	79
Metformin Hcl Er	Metformin Hcl	162	70
Metformin Hcl	Metformin Hcl	145	60
Hydrochlorothiazide	Hydrochlorothiazide	144	64
Metoprolol Tartrate	Metoprolol Tartrate	138	64
Omeprazole	Omeprazole	136	81
Jardiance	Empagliflozin	110	37
Meloxicam	Meloxicam	106	71
Potassium Chloride	Potassium Chloride	104	48
Atenolol	Atenolol	103	45
Glipizide	Glipizide	96	38
Albuterol Sulfate Hfa	Albuterol Sulfate	92	65
Gabapentin	Gabapentin	88	40
Tamsulosin Hcl	Tamsulosin Hcl	88	38
Simvastatin	Simvastatin	84	35
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	82	40
Alendronate Sodium	Alendronate Sodium	74	31
Allopurinol	Allopurinol	72	34
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	72	44
Ozempic	Semaglutide	71	19
Bisoprolol Fumarate	Bisoprolol Fumarate	60	26
Furosemide	Furosemide	58	30
Pradaxa	Dabigatran Etexilate Mesylate	54	24
Trazodone Hcl	Trazodone Hcl	51	22
Triamcinolone Acetonide	Triamcinolone Acetonide	44	30
Humulin N Kwikpen	Insulin Nph Human Isophane	43	16
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	43	21
Humulin N	Insulin Nph Human Isophane	42	14
Terazosin Hcl	Terazosin Hcl	41	18
Clopidogrel	Clopidogrel Bisulfate	40	16
Hydralazine Hcl	Hydralazine Hcl	39	19
Spironolactone	Spironolactone	39	15
Alvesco	Ciclesonide	38	26
Lorazepam	Lorazepam	37	18
Pantoprazole Sodium	Pantoprazole Sodium	37	22
Glipizide Er	Glipizide	36	16
Lactulose	Lactulose	35	suppressed
Sertraline Hcl	Sertraline Hcl	33	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	31	31
Eliquis	Apixaban	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	11
Humulin R	Insulin Regular, Human	28	suppressed
Ezetimibe	Ezetimibe	26	11
Fluoxetine Hcl	Fluoxetine Hcl	26	11
Carvedilol	Carvedilol	25	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	15
Montelukast Sodium	Montelukast Sodium	25	13
Spiriva Respimat	Tiotropium Bromide	25	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	25	suppressed
Finasteride	Finasteride	24	11
Mirtazapine	Mirtazapine	22	suppressed
Alprazolam	Alprazolam	21	suppressed
Ciclopirox	Ciclopirox	21	suppressed
Azithromycin	Azithromycin	20	20
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Ipratropium Bromide	Ipratropium Bromide	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Tradjenta	Linagliptin	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Famotidine	Famotidine	15	15
Ibuprofen	Ibuprofen	15	13
Prednisone	Prednisone	15	13
Colchicine	Colchicine	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Cephalexin	Cephalexin	13	13
Digoxin	Digoxin	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	12	12
Acyclovir	Acyclovir	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	12
Nifedipine Er	Nifedipine	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Felodipine Er	Felodipine	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error